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 Retinopathy of prematurity (ROP) is a major cause of
blindness in infancy [1]. After preterm birth, the developing
retina is exposed to a sudden increase in tissue oxygen ten-
sion resulting in the generation of reactive free radicals which
may lead to impairment of retinal vascular development and
even to loss of already developed retinal capillaries (ROP phase
I). This insufficient vascularization results in retinal hypoxia,
which, in turn, induces a release of various growth factors,
stimulating new and abnormal blood vessel growth (ROP phase
II) [2].
Nitric oxide (NO) is a free radical molecule that plays an
essential role in numerous physiological actions, including
vasoregulation, inhibition of platelet aggregation, and immu-
nological reactions [3]. Endothelial nitric oxide synthase
(eNOS), an isoform of NO-producing enzymes that is fairly
specific to endothelial cells, has been found to play a promi-
nent role in both angiogenesis and vasculogenesis [4].
NO triggers the gene expression and activation of several
angiogenic, cell-migration, and proliferation-inducing factors
including fibroblast growth factor 2, vascular endothelial
growth factor (VEGF), urokinase-type plasminogen activa-
tor, and matrix metalloproteinase [5]. Peroxynitrite, the reac-
tion product of superoxide and NO, is also an important me-
diator of hyperoxia-induced vaso-obliteration [6].
The expression of eNOS is affected by functional poly-
morphisms of the eNOS gene. Particularly, T-786C in the pro-
moter region and 27-bp repeat in intron 4 (eNOS b/a) with
resultant decreased eNOS gene expression have gained more
attention [7,8]. These polymorphisms have already been re-
ported to be associated with diabetic retinopathy in type 1 dia-
betes [9,10] and also with numerous cardiovascular diseases
[7,8].
In view of the key role of eNOS in vasculo- and angio-
genesis and the association of eNOS polymorphisms with dia-
betic retinopathy, we investigated the association between
eNOS T-786C and eNOS 27-bp repeat (b/a) functional polymor-
phisms and the development of severe ROP in low birth weight
infants (LBW).
METHODS
 We monitored 232 patients born with LBW (less than or equal
to 2000 g) between years 2000 and 2003 for T-786C and 27-bp
repeat (b/a) eNOS gene polymorphisms. They were treated in
the neonatal intensive care unit centers of Agost Schöpf-Mérei
Institute of Obstetrics, the first Department of Gynecology
and Obstetrics, and the second Department of Gynecology and
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cause of visual loss in preterm infants. Endothelial nitric oxide synthase (eNOS) is believed to play a central role in both
retinal angiogenesis and vasculogenesis. The aim of this study was to investigate functional genetic polymorphisms of
eNOS in the pathogenesis of ROP.
Methods: eNOS T-786C and 27-bp repeat (eNOS, b: wild-type, a: mutant) genotypes were determined using allele-specific
polymerase chain reaction in 105 low birth weight (LBW) preterm infants treated for ROP (treated group). A control
group was set up and composed of 127 LBW infants with stage 1 or 2 ROP that did not not require treatment (untreated
group).
Results: The genotype distribution of eNOS 27-bp repeat polymorphism was found to significantly differ (p=0.015)
between the two groups, whereas the genotype distribution of eNOS T-786C did not differ (p=0.984) between the groups.
There was no difference in the distribution of either the “a” allele (p=0.153) nor of the C allele (p=0.867) in a groups
comparison. Multiple logistic regression analysis revealed that male gender (p=0.046) and eNOS aa genotype (p=0.047
versus ab genotype and p=0.022 versus bb genotype) were significantly associated severe ROP that required treatment.
The haplotype estimations based on the detected genotype distributions showed that the prevalence of aT and bT haplotypes
was significantly increased in the group treated for ROP.
Conclusions: Functional eNOS 27-bp repeat polymorphism might be associated with the risk of severe ROP, however we
found no association between the eNOS T-786C and the pathogenesis of ROP.
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Obstetrics, Semmelweis University, Budapest. All infants en-
rolled in the study were of Caucasian race. An independent
university ethical committee approved our retrospective study
(licence No: 16/2003). The research followed the tenets of the
Declaration of Helsinki, and informed consent was obtained
from the parents to collect blood samples from their children
for diagnostic and scientific purposes.
All infants underwent ophthalmologic examination.
Maximun ROP stage was assessed and therapy was decided
after consultation with two out of the three available neonatal
ophthalmologists. The patients were divided into two groups
based on requirement for ROP treatment. The first group con-
sisted of 105 infants who had been treated with laser or cryo-
therapy due to ROP stage 2+ or 5. The mean gestational age
was 28±2.5 weeks and mean birth weight was 1150±360 g
(treated group).
The second group enrolled 127 preterm LBW infants with
ROP stage 1 or 2 who did not require cryotherapy/photoco-
agulation. The mean gestational age was 30.5±3.5 weeks and
birth weight was 1300±400 g (untreated group).
DNA for genotyping was extracted from filter papers with
an extracting agent (Chelex®; BioRad, Munich, Germany) ac-
cording to the manufacturers’ instructions. eNOS T-786C SNP
was detected using a procedure described by Nasreen et al
[11]. A 27-bp repeat polymorphism was determined using al-
lele-specific PCR with the following conditions: 30 s at 94 °C
(denaturing), 60 s at 60 °C (annealing), and 30 s at 72 °C (ex-
tension) for 40 cycles. Primer pairs are summarized in Table
1. PCR products were separated on 2.5% agarose gels and
visualized under ultraviolet illumination. By the genotyping
of eNOS T-786C, the C and T alleles gave a 176 and 250-bp
product, respectively, with a 387-bp common product. PCR
amplification of eNOS 27-bp repeat polymorphism resulted
in a product length of 407-bp (b allele) and of 380-bp (a al-
lele, Figure 1).
Harlequin software was used to assess Hardy-Weinberg
equilibrium of eNOS T-786C and eNOS 27-bp repeat polymor-
phisms. The statistical difference, allele frequencies and hap-
lotype distributions among the groups were compared using
the chi-square test. Continuous clinical data were compared
with Student’s t-test. Logistic regression analysis was used to
assess the association between the need for cryotherapy/pho-
tocoagulation and eNOS genotypes. The association was ad-
justed for proven risk factors of ROP [12]: gestational age,
days on supplemental oxygen therapy, and their interaction.
We perfomed our statistical calculations with the R system
[13], using its MASS [14] package.
RESULTS
 Our study enrolled 127 preterm LBW infants with stage 1 or
stage 2 ROP who did not require treatment and 105 preterm
infants whose ROP required therapy. We assessed their geno-
types for the eNOS T-786C and eNOS 27-bp repeat polymor-
phisms.
The clinical characteristics of the patients are shown in
Table 2. Both assessed genotypes were in linkage disequilib-
rium and in Hardy-Weinberg equilibrium, irrespective of ROP
treatment.
Analysis of genotype distributions revealed that the geno-
type distribution of eNOS 27-bp repeat polymorphism was sig-
nificantly different in the treated group (p=0.015). There was
no difference in the genotype distribution of eNOS T-786C poly-
morphism compared to the untreated group (p=0.984; Table
3).
A comparison of the allele frequencies revealed no sig-
nificant difference in the allele distributions of eNOS 27-bp
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Figure 1. Two represetative pictures of eNOS genotyping.  The two
pictures show typical results of the allele-specific PCR reactions for
eNOS 27-bp repeat (A) and eNOS T-786C (B) polymorphisms.
TABLE 1. PRIMER PAIRS USED FOR ALLELE-SPECIFIC POLYMERASE
CHAIN REACTION ANALYSIS
    Gene             Primer (5'-3')
------------   ---------------------------
eNOS T-786C     F: T: CATCAAGCTCTTCCCTGTCT
               R: T0: AGGCCCAGCAAGGATGTAGT
               F: C: GGCAGAGGCAGGGTCAGACG
               R: C0: TTTCTCCAGCCCCTCAGATG
eNOS 27-bp     F: TGGGGGAGATCCTTGCCTTTTC
repeat (b/a)   R: TGAGGGGCTGCACTGGACTGG
Artificially introduced mismatches in the primer sequences are noted
in red.
TABLE 2. PATIENT CLINICAL DATA
     Clinical            Infants not     Infants treated
  characteristics      treated for ROP      for ROP        p values
--------------------   ---------------   ---------------   --------
Number of patients        127              105
Males/Females (N)         60/67            67/38            0.0168
Gestational age
at birth (weeks)          30.5±3.5         28.4±2.5         0.0001
Birth weight (grams)      1300±400         1150±360         0.003
Days on supplemental      7 (0-47)         15 (0-92)        0.0001
oxygen therapy
Gestational age and infant birth weight are shown as mean±SD. The
mean and range are provided for days on, supplemental oxygen
therapy. In the table, ROP represents retinopathy of prematurity.
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repeat “a” and eNOS -786C between the two groups (p=0.153
and p=0.867, respectively; Table 4).
Multiple logistic regression was performed to analyze the
relevance of selected parameters (gender, gestational age, time
on oxygen therapy and the interaction of gestational age and
length of oxygen therapy, and genotypes of eNOS 27-bp re-
peat polymorphism). Results are shown in Table 5. We found
that eNOS aa genotype and male gender were significant pre-
dictors of the onset of ROP requiring treatment among preterm
infants (p=0.047 versus ab genotype and p=0.022 versus bb
genotype and p=0.046 versus females).
Based on the genotype distributions, we estimated and
compared four haplotypes between the treated and untreated
groups. We found that eNOS aT and bT haplotypes were sig-
nificantly increased in the infants treated for ROP compared
to the untreated group (p=0.0001 and p=0.0036, respectively;
Table 6).
DISCUSSION
 Several studies have investigated the role of eNOS in con-
nection with ophthalmologic diseases [9,10,15-20]. Different
eNOS polymorphisms in association with diabetic retinopa-
thy (DR) have been studied extensively. The data are, how-
ever, controversial [9,10,18-20]. De Syllos et al. found no as-
sociation between eNOS T-786C and Glu298Asp polymorphisms
and DR [9]. These results were confirmed by Awata et al. [18].
Yet, a study by Taverna et al. demonstrated that eNOS T-786C
did indeed affect the onset pattern of DR [19]. However, eNOS
27-bp repeat polymorphism was not found to be associated
with DR in either of the studies [18,20].
This is the first study to investigate the relevance of func-
tional eNOS T-786C and 27-bp repeat polymorphisms in the
pathogenesis of ROP. We found that the genotype distribution
of eNOS 27-bp repeat was significantly different between the
study groups; however there was no difference in the frequency
of the “a” allele. Using multiple logistic regression analysis
eNOS aa genotype was proved to be associated with the onset
of ROP requiring treatment. The association was adjusted for
ROP risk factors such as gender, gestational age and time on
oxygen therapy and for the interaction of gestational age and
time on oxygen therapy. We found a significant difference in
the birth weight between the two study groups as well, but
because there was a strong correlation between the gestational
age and birth weight (0.9), we made no adjustment for birth
weight.
There was no significant difference in the genotype dis-
tribution of eNOS T-786C polymorphism nor in the frequency
of -786C allele between the treated and untreated groups.
Haplotype estimations revealed that prevalence of aT and
bT haplotypes was significantly higher in the treated group.
During the first phase of ROP, exposure of the develop-
ing retina to relative hyperoxia results in vaso-obliteration in
which peroxynitrite, the reaction product of superoxide and
NO, has a central role [16].
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TABLE 3. GENOTYPE DISTRIBUTION OF ENOS 27-BP REPEAT AND
ENOS T-786C POLYMORPHISMS TWO GROUPS OF INFANTS WITH
RETINOPATHY OF PREMATURITY
                          Infants not   Infants treated
                          treated for       for ROP       Odds ratio
Gene/region    Genotype   ROP (n=127)       (n=105)       (95% CI)           p values
------------   --------   -----------   ---------------   ----------------   --------
eNOS 27-bp       bb           90              60          1.82 (1.14-2.91)    0.015
repeat (b/a)     ab           36              39
                 aa           1               6
eNOS T-786C       TT           55              47          0.95 (0.64-1.40)    0.984
                 TC           60              79
                 CC           12              9
The chi2 test was used to compare genotype distribution of the differ-
ent polymorphisms between infants with stage 1 or 2 retinopathy of
prematurity (ROP) that was not severe enough to be treated and in-
fants whose severe ROP required treatment. Data are given as the
number of patients.
TABLE 4. ALLELE DISTRIBUTION OF ENOS 27-BP REPEAT AND ENOS
T-786C POLYMORPHISMS IN TWO GROUPS OF INFANTS WITH RETINOPA-
THY OF PREMATURITY
                        Infants not     Infants
                        treated for     treated        Odds ratio
Gene/region    Allele     ROP (%)     for ROP (%)       (95% CI)       p values
------------   ------   -----------   -----------   ----------------   --------
eNOS 27-bp      b a       85% 15%       76% 24%     1.79 (0.87-3.66)    0.153
repeat (b/a)
eNOS T-786C      T C       67% 33%       68% 32%     0.95 (0.64-1.40)    0.867
The chi2 test was used to compare allele distribution of each poly-
morphism between the infants whose retinopathy of prematurity
(ROP) did not require treatment and infants whose ROP was treated.
The frequencies of alleles are given as percentages.
TABLE 5. TRESULTS OF MULTIPLE REGRESSION ANALYSIS
                        Odds ratio
    Variable             (95% CI)        p values
-----------------   ------------------   --------
Male                1.87 (1.26-4.15)      0.046
Gestational age     0.87 (0.71-1.02)      0.071
Length of oxygen    1.20 (0.99-1.40)      0.082
therapy
Gestational age:    0.99 (0.98-1.00)      0.117
length of oxygen
therapy
eNOS 27-bp repeat   0.10 (-2.13-2.34)     0.047
aa versus ab
eNOS 27-bp repeat   0.08 (-2.12-2.28)     0.022
aa versus bb
Models were adjusted by logistic regression analysis for the associa-
tion with retinopathy of prematurity (ROP) requiring treatment among
preterm infants. Association of eNOS genotypes was adjusted for
gender, gestational age and days of oxygen therapy and for the asso-
ciation of gestational age and days of oxygen therapy.
TABLE 6. RESULTS OF THE HAPLOTYPE ANALYSIS
   Position
---------------   Infants not    Infants
27-bp             treated for    treated         Odds ratio
repeat   T-786C      ROP (%)     for ROP (%)      (95% CI)        p values
------   ------   -----------   -----------   ----------------   --------
  a       T           7            28         0.19 (0.09-0.45)    0.0001
  a       C           17           17         1.01 (0.51-2.00)    0.971
  b       T           85           97         0.17 (0.05-0.58)    0.004
  b       C           48           47         1.06 (0.63-1.77)    0.940
Data are given as percentages. The comparison was made in infants
whose retinopathy of prematurity (ROP) did not require treatment
and infants whose ROP was treated.
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Brooks et al. showed that oxygen-induced vaso-oblitera-
tion in the retina was reduced by administration of an NOS
inhibitor or by targeted disruption of the eNOS gene in a mouse
model, indicating a deleterious role of eNOS-derived NO in
the first phase of ROP [15]. Beauchamp et al. found that inhi-
bition of NOS aggravated the retinal vaso-obliteration during
exposure to hyperoxia in a rat model [16].
The vaso-obliterative first phase of ROP leads to retinal
hypoxia, which, in turn, predisposes to the second phase char-
acterized by abnormal vasoproliferation. Evidence suggests
that NO can inhibit angiogenesis under some circumstances,
however, present data are controversial.
Mouse implant and chick chorioallantoic membrane mod-
els can be used to inhibit, angiogenesis by a NO-donor S-
nitroso N-acetyl glutathione [21]. Ando, et al. used eNOS
knockout mice with ischemic retinopathy and detected, a sig-
nificant decrease in neovascularization [17]. Interestingly,
Campochiaro et al. found that NO in low concentrations trig-
gered the expression of VEGF, which then induced
neoangiogenesis [22].
Functional 27-bp repeat polymorphism has a significant
role in eNOS production. Tsukada et al. and Hoffmann et al.
showed a strong association between eNOS 27-bp repeat poly-
morphism and plasma NO metabolite levels in healthy sub-
jects [23,24]. Li et al. also reported that NO metabolite levels
were lower in those who carry the “a” allele [25]. Indeed, it
was demonstrated that nuclear proteins could bind to the 27-
bp repeat sequence and therefore decrease gene transcription.
Decreased NO production may aggravate retinal vaso-
obliteration during the first phase of ROP [15] and then the
neoangiogenesis in the second phase [22]. This could explain
the association found in our study between eNOS 27-bp aa
genotype, leading to decreased eNOS production and severe
ROP. However, the serum levels of NO should be determined
in order to find out the exact association between eNOS 27-bp
repeat polymorphism and the risk and severity of ROP.
It is also conceivable that the observed association be-
tween 27-bp repeat polymorphism and the severity of ROP is
not directly related to NO production capacity. The eNOS gene
is located near other genes, e.g., T-cell antigen receptor con-
stant beta-chain, which has been shown to be strongly associ-
ated with susceptibility to microvascular complications such
as retinopathy in type 1 diabetes [26]. Therefore, it is possible
that the observed association between eNOS 27-bp repeat poly-
morphism and the severity of ROP is the result of linkage dis-
equilibrium with other gene mutations.
In conclusion, we observed that the genotype distribution
of eNOS 27-bp repeat polymorphism was significantly differ-
ent in preterm infants treated for severe proliferating ROP com-
pared to preterm infants infants with stage 1 or 2 ROP that did
not require treatment. We also found that eNOS 27-bp aa geno-
type presented an independent risk factor for ROP requiring
treatment. On the other hand, no association between eNOS T-
786C and ROP was observed. These findings suggest that eNOS
27-bp repeat polymorphism might be associated with the de-
velopment of proliferative ROP and a indicate the importance
of determining the patient’s genetic background when plan-
ning individual therapy.
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